ASSEMBLY BIOSCIENCES, INC. - 8-K Filing
Assembly Biosciences reported first-quarter 2026 financial results with $8.2 million in revenue from its collaboration with Gilead, down from $9.4 million in the same period in 2025. The company ended the quarter with $226.6 million in cash, cash equivalents, and marketable securities, a decrease from $248.1 million at the end of 2025. Research and development expenses were $14.9 million, consistent with the prior year, while net loss attributable to common stockholders was $9.1 million, or $0.54 per share, compared to $8.8 million, or $1.17 per share, in the same period in 2025. (Items: 2.02 Results of Operations and Financial Condition, 9.01 Financial Statements and Exhibits)
Tickers: $ASMB